articleThe Lancet OncologyFeb 5, 2016GREEN OA

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

SAScott AntoniaSBSarah B. GoldbergASAni Sarkis BalmanoukianJEJamie E. ChaftRERachel E. Sanborn

Moffitt Cancer Center · Yale Cancer Center · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

594
total citations
FWCI
52.04
Percentile
100%
References
36
Citations per year

Authors

11

Topics & keywords

Topics
Keywords
  • Durvalumab
  • Tremelimumab
  • Medicine
  • Internal medicine
  • Population
  • Lung cancer
  • Phases of clinical research
  • Immunotherapy
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding